Malaysia to allow commercial sale of 19 vaccines
By Rozanna Latiff and Joseph Sipalan
KUALA LUMPUR, July 16 (Reuters) - Malaysia will soon allow the commercial sale of COVID-19 vaccines manufactured by Chinese firms Sinopharm 1099.HK and Sinovac SVA.O , the science minister said on Friday, as authorities try to ramp up inoculation rates amid surging cases. Malaysia has one of the region's highest number of coronavirus infections per-capita but also one of its fastest vaccination rates. About 39% of its adult population has received at least one dose of a COVID-19 vaccine.
The Sinopharm vaccine, which Malaysia approved on Friday for emergency use, would soon be open for private purchase, science minister Khairy Jamaluddin told a virtual news conference.
Meanwhile, Sinovac vaccines would be available commercially from Aug. 1, after it has completed the delivery of some 15 million doses procured by the government, he said.
Malaysia on Friday reported 12,541 new coronavirus cases, bringing total infections to 893,323, including 6,728 deaths.
Malaysia had previously said it would stop administering Sinovac vaccines after supplies run out, and would instead rely largely on the Pfizer-BioNTech PFE.N 22UAy.DE mRNA vaccine for its national rollout.
On Friday, Khairy clarified that surplus Sinovac shots would remain available for those who may have allergy concerns with other vaccines.
"There is no issue over Sinovac's efficacy," he said.
Malaysia would also consider purchasing more doses from Sinovac in the event of a shortfall of AstraZeneca vaccines from neighbouring Thailand, Khairy said.
Thailand said this week it was considering limiting exports of locally-produced AstraZeneca vaccines to fight its own COVID-19 crisis, a move that could potentially disrupt supplies to its regional neighbours.
Khairy said Malaysia would seek assurances from Thailand that there would be no disruptions to supply.
Reporting by Rozanna Latiff Editing by Raissa Kasolowsky
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。